How much alcohol you drink depends a lot on where you live, USA Today reports.» Read More
Scientists have developed a glucose monitor that is about as invasive as a rub-on tattoo.
An increasing number of people said they failed to get health insurance last year because they didn't know how to apply.
The number of people financially strapped by medical costs has decreased on the heels of the rollout of key Obamacare programs, a new study finds.
Executives at J.P. Morgan's healthcare conference discuss the technologies they believe with change medicine as we know it.
Every state served by the federal Obamacare exchange has already topped the sign-up level that they reached last year.
California's Obamacare exchange has signed up 217,000 new customers, but plans to get more by warning uninsured people about increasing fines.
Biopharma executives at the J.P. Morgan Healthcare Conference talk about this year's biggest challenges.
Louis Navellier says crunching the numbers for stocks that move independent of the market point him to two drug companies and a Chinese retailer.
Ariad CEO Harvey Berger, tells CNBC's Meg Tirrell commercially the company had a good year and provides insight into its new cancer drug, Iclusig.
Vertex CEO Dr. Jeffrey Leiden tells CNBC's Meg Tirrell about the company's new drug trials and focus areas in 2015.
"Any event in life changes one. That was an event that probably changed me in many ways. I think I am a better person," biotech company founder Sam Waksal.
Mike Narachi, Orexigen CEO, speaks with CNBC's Meg Tirrell about its obesity drug and program.
Hans Bishop, Juno Therapeutics co-founder and CEO, discusses promising data for new cancer immunotherapy approaches.
A study says trillions of dollars could be saved in health-care billing and insurance administrative costs over the course of years.
David Cordani, Cigna president & CEO, weighs in on rival Aetna's wage plan and explains Cigna's growth strategy.
Michelle Berrey, Chimerix CEO, discusses the testing of its Ebola drug Brincidofovir in a clinical setting in West Africa, with CNBC's Meg Tirrell.
Valeant CEO Mike Pearson tells CNBC's Meg Tirrell the company is on a mission to prove allegations against the business model are not true. Pearson says Valeant is unlikely to work with Bill Ackman.
The U.K.’s National Health Service, for decades a global case-study in universal healthcare, seems to be facing its biggest ever crisis of confidence.
Martin D. Sass' stock picks are trades in three popular sectors: airlines, pharmaceuticals and asset management.
Sam Waksal, former Imclone Systems CEO, reveals how the ImClone scandal has impacted his life.
Get the best of CNBC in your inbox